Scailyte raises €7.2M Series A round

5 December 2023· Basel, Switzerland· health, precision_medicine, ai, biotech, pure_software, b2b

expand presence in the US market, seeking further partnerships with biotech and pharma companies in the precision oncology space, accelerating Scailyte's impact in the immuno-oncology landscape, expanding business partnerships and market footprint, to promote the discovery of new clinically relevant biomarker signatures

About Scailyte

Stage
Series A
Headquarters
Basel, Switzerland
Founded
2017
Team Size
21–50
Sectors
healthprecision_medicineaibiotechpure_softwareb2b

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH3JWisJoq8OTz14bzi9znpvKR6dD1We4qR7t-JkXIoHZaABl7B27ABVS3Hg80PH_eOiIel8OJiPOLGy01B-gXYCMhry2E84nv0pYhfBX70eKE6BRcMWt0hQD618XiWKUGgzHScvryAPPmt3ntYOFXbL2UUD9sG7QgCdKSvQjZbmVDOo0vvkTTTExMoqwlkcexKF5wURrkcQBuI165P0uJtNdWYBEfu6X37Kg2vY92gfH-bLebMpgoORP5j4sAKo31-n7zn_zI=